Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090 (Q37250169)
Jump to navigation
Jump to search
scientific article published on 17 July 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090 |
scientific article published on 17 July 2013 |
Statements
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study (English)
J V Jovanovic
A Ivey
A M Vannucchi
E Lippert
E Oppliger Leibundgut
N Pallisgaard
S Hermouet
G Nickless
B A van der Reijden
J H Jansen
T Alpermann
S Schnittger
A Bench
K Tobal
B Wilkins
K Cuthill
D McLornan
K Yeoman
S Akiki
J Bryon
S Jeffries
A Jones
M J Percy
S Schwemmers
A Gruender
T W Kelley
S Reading
M F McMullin
H L Pahl
C N Harrison
J T Prchal
T Barbui
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference